Leerink Partnrs Analysts Raise Earnings Estimates for EHC

Encompass Health Co. (NYSE:EHC - Free Report) - Analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for Encompass Health in a research note issued on Wednesday, April 30th. Leerink Partnrs analyst W. Mayo now expects that the company will post earnings per share of $1.31 for the quarter, up from their prior estimate of $1.18. The consensus estimate for Encompass Health's current full-year earnings is $4.80 per share. Leerink Partnrs also issued estimates for Encompass Health's Q3 2025 earnings at $1.11 EPS, Q4 2025 earnings at $1.17 EPS, Q1 2026 earnings at $1.56 EPS, FY2026 earnings at $5.51 EPS, FY2027 earnings at $5.73 EPS and FY2028 earnings at $5.95 EPS.

Other research analysts also recently issued research reports about the company. KeyCorp increased their price target on Encompass Health from $120.00 to $122.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. UBS Group lifted their price objective on Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a report on Monday, April 28th. Barclays raised their price objective on Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Truist Financial restated a "buy" rating and set a $135.00 price target (up from $116.00) on shares of Encompass Health in a report on Monday, April 28th. Finally, William Blair reiterated an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Encompass Health has a consensus rating of "Buy" and an average target price of $120.86.

Encompass Health Trading Up 0.2 %

Shares of EHC traded up $0.23 on Monday, reaching $116.14. 70,772 shares of the company's stock were exchanged, compared to its average volume of 684,486. Encompass Health has a 12 month low of $82.74 and a 12 month high of $118.27. The stock has a market capitalization of $11.71 billion, a P/E ratio of 26.04, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84. The business has a 50 day moving average price of $103.08 and a two-hundred day moving average price of $99.78.

Encompass Health (NYSE:EHC - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping analysts' consensus estimates of $1.19 by $0.18. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The firm's quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.12 earnings per share.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date is Tuesday, July 1st. Encompass Health's payout ratio is presently 14.05%.

Insider Buying and Selling

In other Encompass Health news, EVP John Patrick Darby sold 10,000 shares of the company's stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total value of $1,147,900.00. Following the completion of the sale, the executive vice president now owns 79,710 shares in the company, valued at $9,149,910.90. This represents a 11.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the completion of the transaction, the chief accounting officer now directly owns 69,164 shares of the company's stock, valued at $6,798,129.56. The trade was a 6.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,321 shares of company stock worth $2,142,452. 2.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Tidal Investments LLC raised its position in Encompass Health by 5.7% during the 3rd quarter. Tidal Investments LLC now owns 3,509 shares of the company's stock worth $339,000 after buying an additional 188 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Encompass Health by 22.0% during the third quarter. Franklin Resources Inc. now owns 700,021 shares of the company's stock worth $67,412,000 after purchasing an additional 126,000 shares during the last quarter. GAMMA Investing LLC lifted its position in Encompass Health by 22.1% during the fourth quarter. GAMMA Investing LLC now owns 1,947 shares of the company's stock valued at $180,000 after purchasing an additional 352 shares during the period. Everence Capital Management Inc. purchased a new stake in Encompass Health in the fourth quarter valued at $253,000. Finally, Central Pacific Bank Trust Division grew its position in Encompass Health by 15.1% during the 4th quarter. Central Pacific Bank Trust Division now owns 3,195 shares of the company's stock worth $295,000 after purchasing an additional 418 shares during the period. 97.25% of the stock is owned by institutional investors and hedge funds.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.